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Abstract
Background: Multidrug resistant (MDR) Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia have
a leading role in nosocomial infections, including lower respiratory tract (LRT) infections. When polymicrobial infection by these
three bacteria occurs, colistin against MDR P. aeruginosa and A. baumannii and trimethoprim/sulfamethoxazole (SXT) against S. mal-
tophilia can be an optional antimicrobial strategy.
Objectives: The aim of this study was to investigate the potential synergic effect of colistin-plus-SXT against those MDRP. aeruginosa,
A. baumannii and S. maltophilia isolates that were isolated at the same time, from the same LRT sample of patients.
Methods: Sixty connected isolates from 20 different patients were collected in a two-year study period. The checkerboard method
and time-kill assays were used for synergy testing.
Results: All P. aeruginosa and A. baumannii strains were susceptible to colistin, whereas all S. maltophilia isolates were resistant to
it. Fifteen percent of MDR A. baumannii strains and all S. maltophilia isolates were susceptible to SXT. By the checkerboard method,
colistin-plus-SXT showed synergy in 50%, 35% and 45% of S.maltophilia, MDR P. aeruginosa and MDRA. baumannii strains, respectively.
Antagonistic effect was not found. A time-kill assay was performed on strains which showed synergy by the checkerboard method:
70%, 57% and 56% of S. maltophilia, P. aeruginosa and A. baumannii strains showed the same results. Synergic activity of the combi-
nation was already detected after 6 h incubation in 86% of S. maltophilia isolates and 50% of P. aeruginosa strains. Regrowth of A.
baumannii after 24 hour in the presence of colistin was prevented by the combination. The results gained by CB and TKA methods
correlated in 61% of cases, but theΣFIC values did not correlate with the rate of log10 decrease in TKA. Colistin-plus-SXT combination
had synergic effect on 35% of S. maltophilia, 20% of P. aeruginosa and 25% A. baumannii strains by both methods.
Conclusions: According to our in vitro results, colistin-plus-SXT combined therapy can be used efficiently in clinical practice as no
antagonistic effect was detected. In certain cases colistin-plus-SXT has a synergic effect against MDR P. aeruginosa, A. baumannii and
S. maltophilia.
Keywords: Colistin, Trimethoprim Sulfamethoxazole Drug Combination, Drug Synergism, Pseudomonas aeruginosa, Acinetobacter
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1. Background
Among the non-glucose-fermenting bacteria, Pseu-
domonas aeruginosa, Acinetobacter baumannii and
Stenotrophomonas maltophilia have a leading role in
nosocomial infections, especially in lower respiratory
tract (LRT) infections in mechanically ventilated patients
and in bacteraemia. While S. maltophilia has intrinsic resis-
tance to many antibiotics, limiting treatment options to
trimethoprim/sulfamethoxazole (SXT), fluoroquinolones
and few other antibiotic agents, P. aeruginosa and A. bau-
mannii often show a high level of acquired resistance in
a hospital environment, often making colistin therapy
necessary. The biofilm-forming ability of these bacteria
makes antibiotic treatment even more challenging.
Polymicrobial colonization of the LRT is frequently ob-
served in patients treated in intensive care units (ICU) or in
patients suffering from chronic respiratory tract diseases
with frequent hospital care. Polymicrobial infection can
develop from previous polymicrobial colonization; how-
ever, it is difficult to decide whether the infection is re-
ally polymicrobial or caused by just one member of the
bacterial consortia. Furthermore, differentiation between
polymicrobial colonization and infection of the LRT in ven-
tilated patients with serious underlying diseases is also dif-
ficult.
Stenotrophomonas maltophilia is often part of polymi-
crobial infections. In our centre 58% of S. maltophilia iso-
lated from LRT specimens was cultured as co-pathogen or
co-colonizer in 2013 - 2014. Pseudomonas aeruginosa was
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found to be the most frequent co-pathogen, but A. bau-
mannii was also a significant co-habitant. Although co-
infection/co-colonization by multidrug resistant (MDR) P.
aeruginosa, A. baumannii and S. maltophilia in LRT is rare,
we cannot treat it as a unique and therefore marginal prob-
lem. A rapid and efficacious antimicrobial therapy against
this MDR bacterial consortium is essential.
In a meta-analysis it was demonstrated that colistin
was efficacious and safe for treatment of patients with pul-
monary infection caused by MDR P. aeruginosa or A. bau-
mannii (1). However, considering the low penetration of
colistin in the lung parenchyma after intravenous admin-
istration, there is a certain level of clinical reluctance to
its use for treatment of respiratory tract infections. In-
halational use of colistin provides a high concentration
in airways, and therefore represents a promising therapy
approach (2). Trimethoprim/sulfamethoxazole is the first-
line antimicrobial agent for S. maltophilia infections.
In cases of patients with MDR P. aeruginosa, MDR
A. baumannii and S. maltophilia co-infection in LRT, col-
istin against MDR P. aeruginosa and A. baumannii plus SXT
against S. maltophilia looks to be an optional or obliga-
tory antimicrobial strategy. Colistin-plus-SXT is a com-
bined monotherapy and not an unconventional combi-
nation therapy in such cases. The question is whether
this ‘combination’ has synergy or antagonism on S. mal-
tophilia, P. aeruginosa or A. baumannii.
In recent years combination antibiotic therapy has be-
come an important option against MDR bacteria. Physi-
cians should be supplied with in vitro synergy testing data,
but most of the testing methods (checkekboard method,
time-kill assay) are labour-intensive, therefore they are
rarely performed in routine diagnostic laboratories. Fur-
thermore, results gained by different techniques can be
controversial and difficult to interpret. Especially non-
fermenting bacteria demonstrate the methodical difficul-
ties (3).
2.Objectives
Objective of this study was to determine the in vitro ac-
tivity of the colistin-plus-SXT combination, using different
synergy testing methods, against MDR P. aeruginosa, MDR
A. baumannii and S. maltophilia strains isolated at the same
time from the same LRT samples.
3. Methods
In a two-year study period (2013 - 2014) 392 consecutive
non-duplicate S. maltophilia strains were isolated from LRT
samples. In 58% of cases, other pathogens were isolated
next to S. maltophilia. In 7% of cases, both P. aeruginosa and
A. baumannii were co-isolated and in 5% of cases (n = 20) P.
aeruginosaandA.baumanniifitted the criteria of multidrug
resistance. This study included these 20 MDR P. aerugi-
nosa, 20 MDRA. baumanniiand 20 S.maltophilia isolates col-
lected in the Diagnostic Laboratory of Clinical Microbiol-
ogy, Institute of Laboratory Medicine, Semmelweis Univer-
sity (Budapest, Hungary). The bacterial ‘triplets’ were iso-
lated at the same time from the same sample (tracheal as-
pirate or bronchoalveolar lavage sample) of different pa-
tients. Isolates were identified by the MALDI-TOF mass
spectrometry technique (Bruker Daltonics, Germany). All
strains were isolated from patients treated at ICUs.
Enterobacterial Repetitive Intergenic Consensus PCR
(ERIC-PCR) was used for molecular typing of isolates,
as described by Silbert et al. (4). Bacteria were sus-
pended in 100 µL of PCR-grade water and heated at
100°C for 15 minutes. After centrifugation at 12,000
rpm for 2 minutes, supernatant was removed. One µL
of the supernatant was used as DNA for PCR. Primers
of ERIC1 5’-ATGTAAGCTCCTGGGGATTCAC-3’ and ERIC2 5’-
AAGTAAGTGACTGGGGTGAGCG-3’ (Biocenter, Hungary) and
REDTaq Ready Mix PCR reaction mix (Sigma-Aldrich, USA)
were used for DNA amplification, in 50 µL final PCR reac-
tion volume. PCR conditions were the following: initial
denaturation at 95°C for 2 minutes, 30 cycles at 90°C for
30 seconds, 52°C for 1 minute, 65°C for 8 minutes. Elec-
trophoresis in 1.5% agarose gel stained with 0.01% GelRed
(Biotium, USA) was performed. Isolates that differed by two
or more bands were interpreted as unrelated.
Minimum inhibitory concentrations (MICs) were de-
termined by the broth microdilution method in cation-
adjusted Mueller-Hinton II broth (Becton Dickinson, USA)
(5). Escherichia coli ATCC 25922 and P. aeruginosa ATCC
27853 were used as quality control strains. Colistin (Sigma-
Aldrich, USA) was tested in the range 1 - 512 mg/L in case
of S. maltophilia strains and at 0.06 - 32 mg/l in case of P.
aeruginosa, A. baumannii strains. The MIC values of SXT (Ra-
tiopharm, Hungary) were tested at 0.5 - 256 mg/L and 2 -
1024 mg/L in case of A. baumannii and P. aeruginosa strains,
respectively, and at 0.06 - 32 mg/L in case of S. maltophilia
isolates. To interpret MIC results, EUCAST species-specific
breakpoints were applied, except for the colistin MIC of
S. maltophilia, when the Pseudomonas sp.-specific break-
point was used (6).
Antibiotic combination of colistin-plus-SXT was anal-
ysed initially by a checkerboard technique (CB). Mueller-
Hinton II broth was used. Stenotrophomonas maltophilia
isolates were tested in 7 doubling dilutions of colistin and
11 doubling dilutions of SXT, whereas P. aeruginosa and A.
baumannii strains were tested in 7 doubling dilutions of
SXT and 11 doubling dilutions of colistin. Microbroth plates
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were inoculated with bacteria to yield 5 × 105 CFU/mL in
the 100 µL final volume. Plates were incubated at 35°C
for 18 - 22 hours. Fractional inhibitory concentration in-
dices (ΣFIC) were calculated following the formula: FIC(A)
+ FIC(B) =ΣFIC, where FIC(A) = MIC of antibiotic agent A in
combination/MIC of antibiotic agent A alone and FIC(B) =
MIC of antibiotic agent B in combination/MIC of antibiotic
agent B alone (7). TheΣFIC of two antibiotics tested defines
the effects of antimicrobial agent combinations as antago-
nistic (ΣFIC > 4), indifferent (0.5 < ΣFIC≤4) or synergistic
(FICI≤ 0.5).
When synergy was detected by CB, a time-kill assay
(TKA) was performed at 1xMIC following a previously pub-
lished method (8). When MICs were above the therapeutic
level, SXT was used at 8 mg/L and colistin at 4 mg/L, which
fits the peak serum levels of these agents (9). Twenty ml
of SXT, colistin and SXT-plus-colistin containing Mueller-
Hinton II broth were inoculated with bacteria to yield a
density of 106 CFU/mL in the final volume. Tubes were
incubated at 37°C with constant agitation. After 1, 2, 4,
6 and 24 hours incubation aliquots were removed, seri-
ally diluted in 0.9% sodium chloride solution and plated
on sheep blood agar plates (BioMerieux, France). Colony-
forming units (CFUs) were counted on agar plates after 24
hours incubation at 37°C. The lower limit of detection by
this method was 20 CFU/mL. Synergy was defined as a≥ 2
log10 decrease in CFU/ml at 24 h for the antibiotic combi-
nation compared with its more active constituent (8).
4. Results
According to ERIC-PCR, isolates in the same species
were from different genotypes. All P. aeruginosa and A.
baumannii strains were susceptible to colistin, with MIC50
1 mg/L and MIC90 2 mg/L. Fifteen percent of A. bauman-
nii strains were susceptible to SXT, MIC50 32 mg/L and
MIC90 128 mg/L was found. Pseudomonas aeruginosa strains
showed a high level of intrinsic resistance to SXT, with
MIC50 256 mg/L and MIC90 512 mg/L. AllS.maltophilia strains
were sensitive to SXT, with MIC50 0.25 mg/L and MIC90 1
mg/L, and resistant to colistin, with MIC50 256 mg/L and
MIC90 > 512 mg/L. Results of colistin-plus-SXT combination
tests performed by CB method are summarized in Table 1.
As summarized in Table 2 synergic and indifferent effects
were found, but an antagonist effect was not.
Strains showing synergy by CB method were further ex-
amined by TKA. The tested S. maltophilia, P. aeruginosa and
A. baumannii strains showed synergy in 70%, 57% and 56% of
cases, respectively. The rates of log10 decrease after 6 and
24 h are summarized in Table 3 considering that for most
combinations with colistin against Gram-negative species
initial killing is usually dramatic, but is followed by signif-
icant regrowth. Synergic activity of the combination was
already detected after 6 hours incubation in 86% of S. mal-
tophilia isolates and 50% of P. aeruginosa strains. In the case
of A. baumannii, synergy was detected just after 24 hours in-
cubation. The results gained by CB and TKA methods corre-
lated in 61% of cases, but theΣFIC values did not correlate
with the rate of log10 decrease in TKA. The results of differ-
ent in vitro synergy testing must be synthesized and care-
fully interpreted. Colistin-plus-SXT combination had syn-
ergistic effect on seven S. maltophilia (35%), four P. aerugi-
nosa (20%) and fiveA. baumannii (25%) strains by both meth-
ods.
5. Discussion
The potential synergic effect of colistin-plus-SXT
against MDR P. aeruginosa, MDR A. baumannii and S.
maltophilia isolates was investigated in this study. The
isolates were connected as each one of the three species
was isolated at the same time from the same LRT sample
of patients. Colistin-plus-SXT therapy is an obligatory
antimicrobial strategy in LRT co-infections caused by the
discussed three bacteria.
Co-colonization of patients with carbapenem-resistant
Enterobacteriaceae and A. baumannii or P. aeruginosa has
been shown to be associated with increased antibiotic re-
sistance and mortality (10). As potential interspecies in-
teractions may enhance bacterial virulence and antibiotic
resistance, co-colonization or co-infection of patients with
the intrinsically carbapenem-resistant S. maltophilia and
A. baumannii or P. aeruginosa might be associated with in-
creased antibiotic resistance and mortality. This hypothe-
sis was not considered in previous studies. In our study the
patients’ overall mortality in hospital was 50%. This did not
differ significantly from a previous study where all-cause
mortality of 45% was found in 100 S. maltophilia infections,
of which 62 cases were pneumonia (11). The high mortality
underlines the need for a rapid and effective antimicrobial
therapy.
The folate synthesis inhibitor SXT is the first-line an-
timicrobial drug for S. maltophilia infections. All S. mal-
tophilia strains were sensitive to SXT in our study, which
supports the current antimicrobial guidelines. Colistin
was found to have weak in vitro activity against the stud-
ied S. maltophilia isolates: high level of colistin resistance
(MIC50 256 mg/L) was detected. This shows that colistin
should not be used alone either in S. maltophilia infection
or in S. maltophilia co-infection, but it can have synergic ac-
tivity in combination, as reported in previous studies (12).
The effect of colistin in antibiotic combination is based
on its detergent-like property: it interacts with surface LPS
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Table 1. Summary of Results Gained by CB Method; Effect of Colistin-Plus-SXT Combination was Tested on 20 S. maltophilia, 20 MDR P. aeruginosa and 20 MDR A. baumannii
Strains; Strains were Connected as Each One of the Three Species was Isolated at the Same Time from the Same LRT samplea
Stenotrophomonasmaltophilia Pseudomonas aeruginosa Acinetobacter baumannii
AB1 AB2 AB1 + AB2 AB2 + AB1
∑
FIC AB1 AB2 AB1 + AB2 AB2 + AB1
∑
FIC AB1 AB2 AB1 + AB2 AB2 + AB1
∑
FIC
1 0.25 256 0.062 32 0.375 256 1 32 0.25 0.375 32 1 2 0.25 0.312
2 0.062 256 0.062 4 1.015 128 1 8 1 1.06 8 2 1 0.25 0.25
3 1 512 0.25 8 0.265 512 2 8 1 0.52 128 1 8 0.5 0.56
4 1 8 0.5 2 0.75 128 2 8 1 0.56 64 2 4 0.25 0.187
5 0.25 32 0.125 4 0.625 8 2 1 0.062 0.156 64 0.5 2 0.25 0.53
6 0.25 256 0.062 8 0.281 512 2 8 1 0.52 32 2 4 0.5 0.375
7 0.06 64 0.015 8 0.375 128 1 32 0.125 0.375 64 2 8 0.25 0.25
8 0.5 512 0.062 16 0.151 16 2 0.5 1 0.53 32 2 16 0.25 0.625
9 0.25 256 0.062 16 0.312 512 2 8 0.5 0.265 128 0.5 8 0.25 0.56
10 0.5 32 0.062 2 0.187 512 2 8 1 0.52 32 1 2 0.5 0.56
11 0.25 128 0.125 2 0.52 512 2 16 1 0.53 1 1 0.25 0.125 0.375
12 0.125 256 0.125 16 1.06 512 1 32 0.5 0.56 1 1 0.25 0.125 0.375
13 0.25 64 0.125 16 0.75 512 2 8 0.5 0.265 64 1 8 0.25 0.375
14 0.5 512 0.062 16 0.25 8 1 1 0.25 0.375 128 0.5 4 0.25 0.53
15 0.25 512 0.25 8 1.015 256 0.5 8 0.5 1.03 4 0.5 1 0.25 0.75
16 0.25 512 0.25 8 1.015 512 1 16 0.5 0.53 2 0.5 1 0.25 1
17 0.062 128 0.062 8 1.06 128 0.5 64 0.125 0.75 4 0.125 0.5 0.125 1.125
18 0.25 256 0.25 8 1.03 1024 1 16 0.25 0.265 64 1 32 0.062 0.56
19 0.5 128 0.125 8 0.375 16 0.5 4 0.25 0.75 64 0.5 8 0.125 0.375
20 1 64 0.062 4 0.125 512 1 64 0.5 0.625 16 0.5 1 0.5 1.06
a AB1, MIC value of SXT; AB2, MIC value of colistin; AB1 + AB2, MIC value of SXT in combination with colistin; AB2 + AB1, MIC value of colistin in combination with SXT;ΣFIC values in bold means synergism.
Table 2. Summary of Results Gained by CB Method; Colistin-plus-SXT Combination
was Tested on 20 MDRP.aeruginosa, 20 MDRA.baumanniiand 20S.maltophiliaStrains
Colistin + SXT Combination Tested by
CB Method
No. (%) of Strains Showed
Synergy Indifferent Effect
S. maltophilia 10 (50) 10 (50)
P. aeruginosa 7 (35) 13 (65)
A. baumannii 9 (45) 11 (55)
and phospholipids, disturbing membrane permeability.
Colistin exposure leads to increased permeability to large
or hydrophobic compounds such as SXT (8). Synergic ef-
fect of colistin and SXT against S. maltophilia was found in
47% of isolates by Giamarellos-Bourboulis et al. (13). This is
in concordance with our CB results (synergy in 50% of iso-
lates). When CB and TKA results are evaluated together, the
rate of synergic effect is only in 35%.
In current medical practice SXT is not recommended
for treatment of MDR Acinetobacter infections. In the
majority of studies regarding MDR Acinetobacter spp., the
non-susceptibility rate was > 70%. In our study 85% of
MDR A. baumannii strains were resistant to SXT. Only sin-
gle case reports evaluated SXT for A. baumannii infections,
mainly in combination therapy. Though they considered
therapeutic success, clinical evidence has failed so far
(14). Recent publication report that SXT combined with
colistin might represent an effective therapy for severe
carbapenem-resistant A. baumannii infections (15). In con-
cordance with previously published data, colistin-plus-SXT
was found to display a synergic effect against A. baumannii
isolates: synergy was found in 45% by CB method, but in
25% when results gained by the two methods were synthe-
sized. Similarly to the findings of Nepka et al. the regrowth
of A. baumannii after 24 hours was prevented by colistin-
plus-SXT (15). In case of colistin-resistant A. baumannii
strains colistin-plus-SXT combination demonstrated lim-
ited synergism (16).
Pseudomonas aeruginosa is a poor target for therapy
with SXT (6). Strains showed high level of intrinsic resis-
tance to SXT. The combination of colistin-plus-SXT was syn-
ergistic against 20% of P. aeruginosa. In contrast with our
results, Vidaillac et al. found no activity of colistin-plus-
SXT against their tested colistin-susceptible P. aeruginosa
strains (8).
Discrepancies between our results gained by CB and
TKA indicate that different methods to assess synergic ef-
fects do not provide necessarily comparable results (17).
Nevertheless, the probability of synergy is high in those
cases when a synergic effect is proved by two different tech-
niques. An important finding of our study is that colistin-
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Table 3. Summary of the Synergic Results Gained by TKA; Colistin-Plus-SXT Combination was Tested on Strains Which were Previously Tested by CB andΣFIC was < 0.5
Colistin + SXT Combination No. (%) of strains showed synergy by TKA Previously Determined
Tested by TKA Synergy by TKA Difference in log10 after 6 h Difference in log10 after 24 h
∑
FIC Values
S. maltophilia 7 (70) 5.9 2.4 Sm#1ΣFIC = 0.375
7.7 3.8 Sm#3ΣFIC = 0.265
7.5 3.9 Sm#6ΣFIC = 0.281
2.4 4.7 Sm#7ΣFIC = 0.375
2.7 2.9 Sm#9ΣFIC = 0.312
6.3 3.1 Sm#10ΣFIC = 0.187
6 6 Sm#20ΣFIC = 0.125
P. aeruginosa 4 (57) 7 4.2 Pa#1ΣFIC = 0.375
3.4 2.3 Pa#5ΣFIC = 0.156
6.7 4.1 Pa#14ΣFIC = 0.375
7.2 3.7 Pa#18ΣFIC = 0.266
A. baumannii 5 (56) 3.1 7.3 Ab#2ΣFIC = 0.25
3.3 5.3 Ab#4ΣFIC = 0.094
3.1 7.3 Ab#6ΣFIC = 0.375
2.7 4.8 Ab#11ΣFIC = 0.375
3.6 5.5 Ab#12ΣFIC = 0.375
plus-SXT combination can be used efficiently as no antag-
onistic effect was detected. Furthermore, synergism can
be observed in 20% - 35% of isolates. Regrowth of A. bau-
mannii after 24 hour in the presence of colistin can be pre-
vented by colistin-plus-SXT combination. Of note, previous
studies tested each species separately, whereas in our study
MDR bacteria were investigated in their complex ‘triplet’
as they were isolated from a LRT sample. Two ‘triplets’ out
of 20 showed synergy verified by both methods. In these
cases patients had obvious benefit from combined colistin-
plus-SXT therapy.
The potential interspecies interaction between these
bacteria has to be highlighted. Dominantly in cystic fibro-
sis several studies focused on interaction of P. aeruginosa
with other bacterial species, but only a few have been pub-
lished on the interaction between P. aeruginosa and S. mal-
tophilia. It was found that S. maltophilia increases the risk
of resistance of P. aeruginosa to polymyxin; beta-lactamase
leaking from S.maltophiliaenhances the growth of P. aerug-
inosa in the presence of beta-lactam antibiotic agents; S.
maltophilia might confer a selective fitness advantage to P.
aeruginosa and increase the virulence of P. aeruginosa (18).
The interaction of A. baumannii and S.maltophilia is not dis-
cussed in the literature, except for their ability to increase
each other’s biofilm production (19). It was reported that a
Burkholderia cenocepacia subpopulation highly resistant
to polymyxin B can protect a sensitive P. aeruginosa from
polymyxin B in broth co-culture (20). Similarly, it can be
hypothesized that S. maltophilia highly resistant to colistin
can protect a sensitive P. aeruginosa or A. baumannii from
colistin in broth co-culture. Co-culturing of these bacteria
in sessile form - like they growth together in LRT biofilms
- can be suitable to detect this presumed interaction. Fur-
ther investigations are needed to elucidate this hypothesis.
Further in vitro pharmacokinetic/pharmacodynamic
experiments and animal studies are required to evaluate
the combination of colistin with SXT against MDR Gram-
negative pathogens. Evaluation of the clinical significance
of our observation has to be performed also. The dose-
response relationship of the colistin-plus-SXT combina-
tion must be clarified.
In conclusion, according to our in vitro results we can
state that colistin-plus-SXT combined therapy can be used
efficiently in clinical practice as no antagonistic effect was
detected. In certain cases colistin-plus-SXT has a synergic
effect against MDR P. aeruginosa, A. baumannii and S. mal-
tophilia.
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